Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02431689
Other study ID # 32015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2015
Est. completion date May 2018

Study information

Verified date May 2018
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Poor ovarian response indicates inadequate ovarian response to ovarian stimulation. In the current study the investigators will attempt to compare antagonist and short protocols regarding oocyte as well as embryo quantity and quality. Frozen embryo transfer will be performed in order to abolish iatrogenic effect of stimulation drugs on implantation. Still implantation and pregnancy rates are considered secondary outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 45 Years
Eligibility Inclusion Criteria:

- Patient selection is based on the ESHRE consensus group 2011 definition of poor ovarian response (POR) (Bologna criteria):

- At least two of the following three features must be present:

1. Advanced maternal age (=40 years) or any other risk factor for POR;

2. A previous POR (=3 oocytes with a conventional stimulation protocol);

3. An abnormal ovarian reserve test (i.e. Antral follicle count (AFC) <5-7 follicles or Antimullerian hormone (AMH) <0.5-1.1 ng/ml).

Two episodes of POR after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal Ovarian reserve test (ORT). By definition, the term POR refers to the ovarian response and, therefore, one stimulated cycle is considered essential for the diagnosis of POR. However, patients over 40 years of age with an abnormal ORT may be classified as poor responders since both advanced age and an abnormal ORT may indicate reduced ovarian reserve and act as a surrogate of ovarian stimulation cycle. In this case, the patients should be more properly defined as expected PORs.

Exclusion Criteria:

- Women with endometriosis, endocrinal problems, uterine abnormalities as well as male azospermia.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
IVF/ICSI
controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.

Locations

Country Name City State
Egypt IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini) Cairo
Egypt Kamal Shaeer center of infertility Giza
Egypt Nile IVF center Giza

Sponsors (3)

Lead Sponsor Collaborator
Cairo University Kamal Shaeer center of infertility, Nile Ivf Center, Cairo, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Metaphase II (MII) oocytes Number of MII oocytes collected from each patient on the day of ovum pickup (OPU) 9-14 days from stimulation
Primary Number of good embryos the number of good quality embryos obtained from each patient 3-5 days after ovum pickup
Secondary chemical pregnancy rate positive serum Beta HCG 14 days after embryo transfer 14 days after embryo transfer
Secondary clinical pregnancy rate the detection of intrauterine gestational sac with positive pulsations 5 weeks after embryo transfer
Secondary Implantation rate the ratio between the number of embryos transferred and the number of sacs 5 weeks after embryo transfer
Secondary Early miscarriage rate Pregnancy loss in the first 12 weeks gestation 3 months
Secondary Ongoing pregnancy rate Pregnancy ongoing beyond 12 weeks gestation 3 months
Secondary Live birth rate Pregnancy ending with a live birth 9 months
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A